High expression of neutrophil and monocyte CD64 with simultaneous lack of upregulation of adhesion receptors CD11b, CD162, CD15, CD65 on neutrophils in severe COVID-19

Malgorzata Karawajczyk, Lena Douhan Håkansson, Miklos Lipcsey, Michael Hultström, Karlis Pauksens, Robert Frithiof* and Anders Larsson*

Abstract

Background and Aims: The pronounced neutrophilia observed in patients with coronavirus disease 2019 (COVID-19) infections suggests a role for these leukocytes in the pathology of the disease. Monocyte and neutrophil expression of CD64 and CD11b have been reported as early biomarkers to detect infections. The aim of this study was to study the expression of receptors for IgG (CD64) and adhesion molecules (CD11b, CD15s, CD65, CD162, CD66b) on neutrophils and monocytes in patients with severe COVID-19 after admission to an intensive care unit (ICU).

Methods: The expression of receptors was analyzed using flow cytometry. EDTA blood from 23 patients with confirmed COVID-19 infection was sampled within 48 h of admission to the ICU. Leukocytes were labeled with antibodies to CD11b, CD15s, CD65s, CD162, CD64, and CD66b. Expression of receptors was reported as mean fluorescence intensity (MFI) or the percentage of cells expressing receptors.

Results: Results are presented as comparison of COVID-19 patients with the healthy group and the receptor expression as MFI. Neutrophil receptors CD64 (2.5 versus 0.5) and CD66b (44.5 versus 34) were increased and CD15 decreased (21.6 versus 28.3) when CD65 (6.6 versus 4.4), CD162 (21.3 versus 21.1) and CD11b (10.5 versus 12) were in the same range. Monocytes receptors CD64 (30.5 versus 16.6), CD11b (18.7 versus 9.8), and CD162 (38.6 versus 36.5) were increased and CD15 decreased (10.3 versus 17.9); CD65 were in the same range (2.3 versus 1.96).

Conclusion: Monocytes and neutrophils are activated during severe COVID-19 infection as shown by strong upregulation of CD64. High monocyte and neutrophil CD64 can be an indicator of a severe form of COVID19. The adhesion molecules (CD11b, CD162, CD65, and CD15) are not upregulated on otherwise activated neutrophils, which might lead to relative impairment of tissue migration. Low adhesion profile of neutrophils suggests immune dysfunction of neutrophils. Monocytes maintain upregulation of some adhesion molecules (CD11b, CD162) suggesting the persistence of an increased ability to migrate into tissues, even during a severe stage of COVID-19. Future research should focus on CD64 and CD11b kinetics in the context of prognosis.

Keywords: COVID-19, CD64, CD11b, CD15, CD65, CD 162, neutrophil, monocyte

Received: 25 May 2021; revised manuscript accepted: 2 July 2021.
Introduction

Viral infection often causes a rise in lymphocyte but not in neutrophil count in peripheral blood. In patients with coronavirus disease 2019 (COVID-19) an opposite trend has been observed, i.e., an elevated neutrophil count but not a lymphocyte increase. The progressing lymphocytopenia and neutrophilia are signs of a less favorable prognosis.1,2 Although neutrophils are potent antimicrobial cells, they can contribute to host tissue damage when hyperactive.3 For example, production of neutrophil extracellular traps (NET-osis) by activated neutrophils is a proposed contributing factor in organ damage in COVID-19 patients.4 Moreover, increased levels of neutrophil-associated cytokines originating from NLRP3 inflammasome is correlated with organ damage in COVID-19 patients.5 A pattern of 25 granulocyte-associated markers has been proposed recently to predict critical illness and mortality in COVID-19.6

Bacterial superinfections have been identified in 8% of hospitalized COVID-19 patients, but 72% of hospitalized COVID-19 patients have received antibiotics despite the lack of evidence for bacterial coinfection.7 Overuse of antibiotics results in increased antibiotic resistance.8 Antibiotic resistance results in longer hospital stay, high mortality and morbidity, and increased hospital burden.9 Generally, the risk of superinfection increases with hospitalization time and the length of time on a ventilator.10 Because inflammatory parameters are increased due to viral infection and organ damage, it might be difficult to distinguish the inflammation caused by COVID-19 from bacterial superinfections during hospitalization. This may be a reason for widespread antibiotic use in COVID-19 patients without verified bacterial infections.

The high-affinity receptor for immunoglobulin G (FcγRI) – CD (cluster of differentiation) 64 has an important role in innate immunity. FcγRI is a cyto-activating receptor: for example, its crosslinking induces cellular responses, including phagocytosis, the release of inflammatory mediators, antibody-dependent cell-mediated cytotoxicity, and antigen presentation.11 CD64 is expressed constitutively on monocytes, but in neutrophils it is stored inside the cell, and mobilized to the surface upon priming.12 Neutrophil expression of CD64 has been shown previously to perform well as a biomarker of bacterial infection,13,14 and even to distinguish bacterial from viral infections.15,16 Neutrophil CD64, as well as neutrophil and monocyte CD11b expression, has shown good discriminatory power between severe septic and non-septic intensive care unit (ICU) patients (operation, trauma, intoxication, cerebral hemorrhage) and in distinguishing infection from disease flare in patients with autoimmune disease.17,18 Neutrophil CD64 is a useful marker in the diagnosis and prediction of survival in ICU patients with ventilator-acquired pneumonia and even superior to procalcitonin and CRP in the diagnosis of sepsis in ICU patients.19,20

Leukocyte adhesion to endothelial cells and subsequent transmigration from the bloodstream to tissues is facilitated by the adhesion molecules: selectins and integrins and their ligands. CD15s, CD65s (E-selectin ligand), and CD162 (P-selectin ligand) facilitate rolling, and CD11b (a member of integrin family) promotes adhesion and thereby transmigration of leukocytes from the blood vessels to the extravascular compartment.21

The integrin receptor CD11b has been upregulated on neutrophils and monocytes upon exposure to viral and bacterial infections.22 It is suggested to be a useful marker of neonatal sepsis.23 A recent study of COVID-19 patients demonstrated a decrease in granulocyte CD11b expression.6 Blocking CD11b has been proposed to have a beneficial effect on sepsis outcome.24

Little is known about the expression of these molecules in infections. Inhibition of CD162 results in attenuation of leukocyte adhesion and extravasation to tissues in animal models of septic shock,25 which make selectin ligands attractive targets for clinical intervention. Neutrophil CD162 has been shown to decrease during exacerbation of COPD caused by infection.26 In vitro, interleukin–8 (IL-8) and formyl-methionyl-leucyl-phenylalanine (f-MLP) downregulate CD15 and CD162.27

The knowledge of CD65s in the aspect of infection is scarce. In vitro experiments showed that the CD65 expression on neutrophils increases upon stimulation with f-MLP but not with IL-8.27 CD65 has been shown recently to play a role in the extravascular infiltration of acute myeloid leukemia cells.28
CD66b is a member of the carcinoembryonic antigen-related cell adhesion molecule 8 family. It is upregulated upon neutrophil activation due to mobilization of granules to the cell surface. CD66b is increased in rheumatic arthritis, bacterial and viral infection, and after surgery.

Given the proposed role of neutrophils in COVID-19 infection, it seems likely that the neutrophil activation markers may be useful in monitoring inflammation and, by that, assess the outcome.

This study aims to investigate the activation of blood neutrophils and monocytes from COVID-19 patients by determining the expression of receptors for IgG (CD64), adhesion molecules (CD11b, CD162, CD65s, CD15s), and cell activation (CD66b), and evaluating whether they can be potential markers of inflammation in severe COVID-19, especially in the context of hospital-acquired bacterial superinfection and to clinical prognosis assessment.

Materials and methods

Participants
All the patients were adults admitted to the general ICU at Uppsala University Hospital from 22 April 2020 to 17 May 2020. The patients were included after written informed consent was obtained from themselves or from their next-of-kin for patients unable to consent. COVID-19 was diagnosed by polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). The protocol of the study was registered a priori [ClinicalTrials.gov identifier: NCT04316884]. The study was approved by the National Ethical Review Agency (EPM; No. 2020–01623) and adheres to the ethical practices described in the Declaration of Helsinki and its subsequent revisions.

The control group comprised of 20 healthy blood donors who made their routine control complete blood count (CBC) in connection with their visit to the local blood center. Blood that was left over after performing the routine analyses was used for receptor expression measurements. Control samples were analyzed anonymously, according to the ethical permit from the Uppsala University Ethical Committee (Dnr: 01-367).

Study design
EDTA blood for analysis of receptor expression were collected within 48 h after COVID-19 patients admission to the ICU. The control group consisted of health blood donors. Receptors expression was analyzed within 6 h from sampling.

Lithium heparin blood for C-reactive protein (CRP), procalcitonin, ferritin, N-terminal pro-brain natriuretic peptide (NT-pro-BNP), D-dimer, and troponin I was collected routinely at 0600 hours for all COVID-19 patients. For plasma markers, the normal reference ranges used at the Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, were used for comparison.

Flow cytometry
Labelling of leukocytes with antibodies to cell surface antigens. Leukocytes in whole blood were fixed with 0.2% paraformaldehyde and the erythrocytes lysed by ammonium chloride according to Hamblin et al. After two washes with PBS containing 0.1% human albumin [PBS–0.1% human serum albumin (HSA)] the leukocytes were incubated for 30 min at +4°C in two tubes with fluorescence labelled antibodies. Tube 1 contained anti-CD11b-FITC (Beckman Coulter (BC) Marseilles, France), anti-CD14-PC7 (BC), anti-CD15s-BV421 (BD Biosciences, San Jose, CA, USA) and anti-CD66b-APC (BC), and tube 2 anti-CD65s-FITC (Bio-Rad, anti-CD14-PC7 (BC), Oxford, UK), anti-CD64-APC-AlexaFluor750 (BC), and anti-CD162-PE (BD Biosciences). After incubation, all the samples were washed twice with ice cold PBS and thereafter diluted in PBS–0.1% HSA. The tubes were placed in the dark at 4°C until the flow cytometry analysis was performed.

Flow cytometry analysis. Flow cytometry analysis was performed using the flow cytometer Navios (Beckman Coulter, Bromma, Sweden). Granulocytes were identified by their forward and side scatter dot-plot profile and monocytes by their expression of CD14. A gate was set around the granulocyte and the CD14 positive monocyte population. The proportion (%) of granulocytes and monocytes expressing the receptor and the mean fluorescence intensity (MFI) of the granulocyte and monocyte population were assayed. A minimum of 10,000 events in the granulocyte gate was analyzed.
**CRP, procalcitonin, ferritin, troponin I, NT-pro-BNP**

Lithium heparinized plasma was used to analyze inflammation and organ damage markers. All analyses were performed on Architect ci16200 (Abbott, Abbott Park, IL, USA) as standard samples.

**Statistical analysis.** Data are presented as mean and standard error of mean (SEM). To describe the predictive value of the studied receptors for mortality after 30 days and their corresponding 95% confidence intervals (CI), area under the curve was obtained from the receiver operating characteristic curve (AUC-ROC) using MedCalc, version 14 (MedCalc Software, Ostend, Belgium). The best cut-off was defined at the maximal distance from ROC curve and the diagonal.

**Results**

**Patient characteristics**

Samples for flow cytometry were obtained from 23 patients (8 women, 15 men) with a median age of 64 (range 35–84) years. Patients were admitted to the ICU on the average of the 9th day of clinically defined disease (range 4–20 days). The main reason for admission was respiratory insufficiency. All patients had fever (median 39°C, range 38–40°C). The Simplified-Acute-Physiology-Score (SAPS 3) on arrival was 52 (range 32–69). The mean body mass index was 28 (range 21–43 kg/m²). The group for which flow cytometry samples were collected was not different from the full cohort of 53 COVID-19 patients treated at the ICU during this time. Table 1 shows the demographic details of the entire cohort and group for which neutrophil and monocyte receptors were measured. Dropouts from the whole cohort was due to the availability of the flow cytometry analysis.

The control group for receptor measurements consisted of 20 healthy blood donors from the local blood collection center.

**Receptors**

Adhesion receptors: CD11b, CD15s, CD65s and CD162. Data are presented in Figure 1a,b and Table 2.

Expression of the integrin receptor CD11b increased significantly on monocytes but not on neutrophils in COVID-19 patients compared with healthy controls. Expression of CD15s decreased on both monocytes and neutrophils in the COVID-19 patient group compared with healthy controls. The level of the E-selectin ligand CD65s expression on monocytes and neutrophils did not differ between COVID-19 patients and healthy controls. The expression of the P-selectin ligand CD162 was slightly higher on monocytes from COVID-19 patients compared with healthy controls. Neutrophil CD162 expression showed similar levels in COVID-19 patients as in healthy controls.

**High-affinity IgG receptor FcγRI CD64.** Expression of CD64 on monocytes and neutrophils increased significantly in the COVID-19 patient group compared with the healthy controls. Likewise, a proportion of neutrophils expressing CD64 increased significantly (Figure 2 and Table 2).

**Activation marker CD66b.** The expression of CD66b on neutrophils was elevated significantly in COVID-19 patients compared with healthy controls. CD66b is not expressed on monocytes (Table 1).

**Inflammation markers CRP, ferritin, procalcitonin and organ dysfunction markers troponin I, NT-pro-BNP, and D-dimer**

The mean plasma levels of the inflammation markers CRP, procalcitonin, and ferritin were elevated above the normal range in the COVID-19 patient group (Table 3). The CRP levels were above 50 mg/L in all but two of the COVID-19 patients. Procalcitonin levels above 0.25 μg/L were noted in 17/23 patients. Low procalcitonin levels <0.25 mg/L were seen in 7/23 COVID-19 patients. Plasma levels of NT-pro-BNP, troponin I and D-dimer were increased above the normal range in most of the patients (Table 3).

**Correlation between plasma inflammation markers and receptors**

The correlations between plasma markers of inflammation and all measured receptors were
Table 1. Patient characteristics: comparison of the whole cohort of patients in an ICU with the studied subgroup. The neutrophil marker group does not differ from the whole cohort.

|                          | All ICU patients from 22/4 to 17/5 | Neutrophil marker patients |
|--------------------------|------------------------------------|-----------------------------|
|                          | \( n = 53 \)                        | \( n = 23 \)                |
| Age (years, SD)          | 61 15                               | 64 14                       |
| Female (\( n, \% \))     | 13 25%                              | 8 35%                       |
| BMI (mean, SD)           | 30 6                                | 29 6                        |
| SAPS3 (mean, SD)         | 52 8                                | 53 10                       |
| Comorbidities            |                                    |                             |
| Lung disease (\( n, \% \)) | 11 21%                             | 4 17%                       |
| Hypertension (\( n, \% \)) | 24 45%                             | 12 52%                      |
| Heart failure (\( n, \% \)) | 3 6%                              | 3 13%                       |
| Ischemic heart disease (\( n, \% \)) | 6 11%                          | 3 13%                       |
| Vascular disease (\( n, \% \)) | 8 15%                             | 5 22%                       |
| Thromboembolic disease (\( n, \% \)) | 2 4%                           | 2 9%                        |
| Liver failure (\( n, \% \)) | 1 2%                               | 1 4%                        |
| Malignant disease (\( n, \% \)) | 0 0%                            | 0 0%                        |
| Diabetes (\( n, \% \))   | 14 26%                              | 6 26%                       |
| Neurological disease (\( n, \% \)) | 3 6%                           | 2 9%                        |
| Psychiatric disease (\( n, \% \)) | 3 6%                           | 1 4%                        |
| Complications/outcomes   |                                    |                             |
| Thrombotic events (\( n, \% \)) | 8 15%                           | 1 4%                        |
| Critical illness neuro/myopathy (\( n, \% \)) | 6 11%                         | 3 13%                       |
| Delirium (\( n, \% \))   | 3 6%                                | 2 11%                       |
| Secondary infection (\( n, \% \)) | 27 51%                         | 9 39%                       |
| 30-day mortality (\( n, \% \)) | 12 23%                         | 6 26%                       |
| Medications              |                                    |                             |
| Corticosteroid treatment (\( n, \% \)) | 4 8%                       | 1 4%                        |
| ACEi/ARB treatment (\( n, \% \)) | 15 28%                       | 10 43%                      |
| Anticoagulant treatment (\( n, \% \)) | 12 23%                       | 6 26%                       |

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; ICU, intensive care unit; SAPS3, Simplified Acute Physiology Score III; SD, standard deviation.
Table 2. Expression of receptors on neutrophils and monocytes in COVID-19 patients and healthy groups. Data are expressed as mean ± SEM and range (min–max).

| Receptor expression per cell MFI | Patients Mean/±SEM/range | Healthy median/±SEM/range | p Value Mann–Whitney | Benjamin–Hochberg p value. Significant with f 0.05 |
|----------------------------------|---------------------------|---------------------------|-----------------------|-----------------------------------------------|
| CD11b Neutrophils                | 10.6 ± 0.64 (3.6–18.7)    | 11.7 ± 0.8 (4.8–16.6)    | 0.21                  | 0.267350479*                                |
| CD11b Monocytes                  | 19.1 ± 1.3 (8.25–30.6)    | 9.1 ± 0.6 (4.7–12.4)     | 0.000001*             | 0.000028*                                   |
| CD66b Neutrophils                | 46.2 ± 3.1 (20.6–74)      | 34.02 ± 2.2 (15.9–55.7)  | 0.0136*               | 0.019776578*                                |
| CD15s Neutrophils                | 22 ± 1.3 (13.5–33.1)      | 27.7 ± 1.6 (18.5–40.1)   | 0.0135*               | 0.019776578*                                |
| CD15s Monocytes                  | 11.1 ± 0.9 (3.8–18.6)     | 17.7 ± 1.4 (7.3–26.6)    | 0.0027*               | 0.004741654*                                |
| CD65 Neutrophils                 | 5.9 ± 0.44 (2.3–10.6)     | 4.9 ± 0.44 (2.6–9.6)     | 0.0322*               | 0.043037243*                                |
| CD65 Monocytes                   | 2.3 ± 0.14 (1.0–3.7)      | 2.32 ± 0.14 (1.32–5.6)   | 0.4114                | 0.414643309                                 |
| CD 162 Neutrophils               | 21.6 ± 0.7 (16.5–30.4)    | 20.4 ± 0.64 (16.5–30.4)  | 0.3684                | 0.393062398                                 |
| CD162 Monocytes                  | 39.2 ± 1.2 (27.9–51.1)    | 36.7 ± 0.72 (26.9–40.7)  | 0.0018*               | 0.003659487*                                |
| CD64 Neutrophils                 | 3.7 ± 0.6 (0.52–9.7)      | 0.67 ± 0.7 (0.39–1.7)    | 0.0000*               | 0.000001*                                   |
| CD64 Monocytes                   | 32.02 ± 2.1 (14.3–53.9)   | 16.3 ± 0.6 (8.99–21.4)   | 0.0000*               | 0.000033*                                   |

Proportion of cells expressing receptor %

| CD64 Neutrophils%                | 77.8 ± 5.6 (16.2–100)     | 16.3 ± 0.6 (6.9–55.9)    | 0.0000*               | 0.000001*                                   |

*Differences are considered significant if f < 0.05 as calculated with the Benjamin–Hochberg test and p < 0.01 the Mann–Whitney test. COVID-19, coronavirus disease 2019; MFI, mean fluorescence intensity; SEM, standard error of the mean.

Figure 1. [a] Expression of CD11b and CD15s on monocytes and neutrophils. Bars represent median values. A difference is considered significant if p < 0.05 as calculated with the Benjamin–Hochberg test and p < 0.01 with the Mann–Whitney test. • CD11b monocytes, ▪ CD11b neutrophils, ○ CD15s monocytes, □ CD15s neutrophil. (b) Expression of CD65 and CD162 on monocytes and neutrophils. Bars represent the mean value. A difference is considered significant if p < 0.05 as calculated with the Benjamin–Hochberg test and p < 0.01 with the Mann–Whitney test. • CD65 monocytes, ▪ CD65 neutrophils, ○ CD162 monocytes, □ CD162 neutrophils. COVID-19, coronavirus disease 2019; MFI, mean fluorescence intensity.
Figure 2. Expression of CD64 on monocytes and neutrophils. Bars represent the mean value. A difference is considered significant if \( p < 0.05 \) as calculated with the Benjamin–Hochberg test and \( p < 0.01 \) with the Mann–Whitney test. (●) CD64 monocytes MFI, (●) CD64 neutrophils MFI, (□) CD64 neutrophils %.

COVID-19, coronavirus disease 2019; MFI, mean fluorescence intensity.

Table 3. Plasma levels of inflammatory and organ damage markers in COVID-19 patients.

| Marker       | Mean ± SEM | Min–max   | Reference interval          | Units   |
|--------------|------------|-----------|-----------------------------|---------|
| CRP          | 174 ± 19   | 14–351    | <5                          | mg/l    |
| Procalcitonin| 0.67 ± 0.31| 0.08–6.5  | <0.05                       | μg/l    |
| Ferritin     | 1613 ± 267 | 312–5563  | 25–310                      | μg/l    |
| Troponin     | 16 ± 6.9   | 1–137     | <16 women                   | ng/l    |
|              |            |           | <35 men                     |         |
| NT-pro-BNP   | 425 ± 355  | 105–7330  | Women <50 years <150        | ng/l    |
|              |            |           | Women >50 years <330        |         |
|              |            |           | Men <50 years <90           |         |
|              |            |           | Men >50 years <230          |         |
| D-dimer      | 1.5 ± 0.15 | 0.2–3.1   | Under 51 years <0.50        | mg/l FEU|
|              |            |           | 51 years <0.51              |         |
|              |            |           | 51 < 0.52 etc.              |         |
|              |            |           | 90 years <0.9               |         |

COVID-19, coronavirus disease 2019; CRP, C-reactive protein; FEU, fibrinogen equivalent units; SEM, standard error of the mean.

calculated. Statistically significant correlations were found for CRP and procalcitonin \( (p = 0.00058) \) and for neutrophil CD64 MFI and procalcitonin \( (p = 0.018) \) (Table 4). There were no significant correlations
between other receptors and CRP or procalcitonin (p < 0.05).

**Bacterial infection**

Of the 23 patients, 20 (87%) received antibiotic therapy at sample collection. Only 10 had a microbiologically verified bacterial superinfection. Causative microorganisms were *Staphylococcus aureus*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Enterococcus faecalis*, *Escherichia coli*, Serratia marcescens, *Pseudomonas aeruginosa*, and *Candida albicans*; 7/10 had polymicrobial flora. Microorganisms were present in different biological materials such as blood, urine, tracheal secretion, or nasopharyngeal swabs. There was no difference in receptor levels, procalcitonin, or CRP between patients with positive and negative bacterial culture.

**Prognostic values of the studied receptors and plasma markers**

Of the 23 COVID-19 patients, 6 died within 30 days from admission to hospital. To analyze the ability of receptors, inflammation, and organ damage markers to distinguish between survivor and non-survivor in the whole COVID-19 group, we calculated the ROC curve for each of the parameters. Data are presented in Table 5 and Figure 3.

Among receptors, the strongest association with mortality was shown by monocyte CD15 (p = 0.0004), followed by monocyte CD64 (p = 0.0015). Other receptors did not reach a statistical significance of p < 0.05. Among the organ damage markers, NT-pro-BNP (p = 0.0001) and troponin I (p < 0.0001) were also significantly associated with mortality. All four markers showed strong negative predictive value at chosen cut-off points. None of the clinically used inflammation markers (CRP, procalcitonin and ferritin) were associated significantly with mortality.

**Discussion**

In some patients, COVID-19 can take a very severe course, with pronounced inflammation leading to severe tissue damage. Neutrophils and monocytes

---

**Table 4.** Correlation between inflammation markers and expression of studied receptors calculated with Spearman rank. p < 0.05 was considered significant.

| Marker                        | N  | Spearman R | T(N-2) | p value |
|-------------------------------|----|------------|--------|---------|
| Procalcitonin and cd64neutrMFI| 23 | 0.585      | 3.308  | 0.0033  |
| Procalcitonin and cd64neutr%  | 23 | 0.663      | 4.058  | 0.000577|
| Procalcitonin and CRP         | 23 | 0.488      | 2.562  | 0.01816 |

CRP, C-reactive protein.

**Table 5.** The diagnostic performance of studied receptors expression and plasma levels of cardiac damage markers.

| Marker            | AUC | SE  | 95% CI  | Significance level p (area = 0.5) | Cut-off value | Sensitivity | Specificity | NPV  | PPV  |
|-------------------|-----|-----|---------|-----------------------------------|---------------|-------------|-------------|------|------|
| mCD15s            | 0.823 | 0.09 | 0.603–0.951 | 0.0004                            | <11.7         | 100         | 62.5       | 100  | 50   |
| mCD64             | 0.794 | 0.093 | 0.576–0.932 | 0.0015                           | >29.1         | 100         | 64.7       | 100  | 50   |
| NT-pro-BNP        | 0.833 | 0.087 | 0.621–0.954 | 0.0001                           | >595          | 83.3        | 76.5       | 93   | 56   |
| Troponin I        | 0.863 | 0.077 | 0.656–0.969 | <0.0001                          | >19           | 100         | 76.4       | 100  | 50   |

AUC, area under the curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SE, standard error.
play an important role in the development of exaggerated inflammatory response. Expression of surface receptors on neutrophils and monocytes reflects state of their activation and can be used as a marker of ongoing inflammation.

The main result of this study is that neutrophils and monocytes are activated in patients with critical COVID-19 infections as shown by upregulation of CD64. No upregulation of neutrophil adhesion molecules (CD11b, CD15s, CD65s, CD162) was observed, whereas monocytes showed upregulation of adhesion molecules (CD11b and CD162).

Receptor expression
Selectins are responsible for the first step of adhesion to the blood vessel wall, e.g., rolling and integrins facilitates the second step, e.g., adherence. Neutrophils and monocytes express ligands for the P- and E-selectin (CD162, CD65, CD15s) and integrin receptor (CD11b).

Our group of COVID-19 patients showed a strong upregulation of the beta2-integrins (CD11b) on monocytes but not on the neutrophils, which differs from reports on influenza and bacterial infections but aligns with the report on COVID-19.6,22

Severe COVID-19 infection did not significantly change neutrophil expression of the selectin ligands CD162 and CD65s, whereas there was a reduction in expression of CD15s.

Lack of upregulation of the neutrophil selectin ligands (CD162 and CD65s) and integrin receptor (CD11b) may impair extravascular neutrophil transmigration to tissues and lead to an increased number of neutrophils in peripheral blood. Neutrophilia is characteristic of severe COVID-19 and can be due to increased bone marrow production, decreased migration from blood to tissues, or both. Impaired neutrophil extravascular migration can be a part of immune paralysis.

Figure 3. ROC curves for predicting death. Dotted lines show ROC curve, light grey CI (a) monocyte CD15 AUC = 0.82 (b) monocyte CD64 AUC = 0.79, (c) troponin AUC = 0.86 and (d) NT-pro-BNP AUC = 0.833. AUC, area under the ROC curve; CI, confidence interval; COVID-19, coronavirus disease 2019; MFI, mean fluorescence intensity; ROC, receiver operating characteristic.
like that observed in sepsis patients or just part of a regulatory mechanism restricting the number of neutrophils in the tissue. The patients in our study were sampled, on average, on the 11th day of disease, making it impossible to assess whether normal receptor levels reflect a lack of activation or emerging inhibition due to regulatory mechanisms. The differences between previous studies and ours may also be caused partly by the kinetics of the CD11b expression. CD11b has been shown to have rapid up- and down-regulation depending on the activator. Lack of upregulation of neutrophil CD11b, CD162, CD15s, and CD65s in otherwise activated neutrophils can be a sign of immune dysfunction in COVID-19.

Pronounced increase of monocyte CD11b together with slight increase of monocyte CD162 may be enough to sustain enhanced monocyte migration even in the late stage of disease.

CD64, the high-affinity receptor for IgG, is expressed constitutively on monocytes but neutrophils express CD64 upon priming.

In the COVID-19 patient group, CD64 was strongly upregulated on neutrophils and monocytes compared with healthy controls. Similar findings were reported in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection and adults with severe COVID-19. Very high neutrophil CD64 (MFI > 1.8 and >80%) has been seen in patients with bacterial infection. Lower-grade CD64 expression has been observed in patients with influenza or trauma.

The question arises whether the very high expression of neutrophil and monocyte CD64 in COVID-19 patients is due to neutrophil activation by bacterial superinfection or by inflammation caused by COVID-19. In the first case scenario, CD64 could be used as a marker for upcoming bacterial superinfection; in the second case, it could be a prognostic marker for tissue damage by inflammation. Our results do not conclusively support the hypothesis about the relation between bacterial superinfection and neutrophil CD64. A reason could be that most of the patients received broad spectrum antibiotics, which protects from infection. Another reason could be that inflammation in severe COVID-19 causes high upregulation of CD64. Kinetic studies of CD11b and CD64 before the start of antibiotic therapy are needed to clarify their usefulness as markers of bacterial superinfection.

High upregulation of both neutrophil and monocyte CD64 seems to be a characteristic feature of severe COVID-19. An increase in neutrophil CD66 in another sign of neutrophil activation.

**Correlation between inflammation markers and receptors**

The relation between CRP and procalcitonin was significant but quite weak. A large variation in CRP levels, procalcitonin, and ferritin observed in the patient group reflects complex regulatory mechanism of immune response in each individual patient. The correlation between neutrophil CD64 and procalcitonin was a little bit stronger than that between CRP and procalcitonin, suggesting that neutrophil CD64 and procalcitonin increase are partially regulated by similar mechanisms. Both markers have been proposed previously by many as specific markers of bacterial infection. The lack of correlation between a clinically used biomarker of infection such as CRP and procalcitonin and monocytes receptors such as monocyte CD11b, and monocyte CD64 MFI, suggest different regulatory mechanisms for each marker. This makes monocyte receptors interesting for future studies as an independent marker of inflammation in COVID-19.

**Prognostic values of markers**

The cardiac damage markers in COVID-19 group showed associations with mortality according to the ROC analysis. This is in agreement with other reports on COVID-19. The predictor value of the cardiac damage parameters is related to cardiovascular insufficiency in critical illness. Plasma inflammation markers did not reach significant associations with death in our study group. This is contrary to the finding of many others, but there was significant heterogeneity between studies.

Among cell receptors, even a slight depression of monocyte CD15s seems to indicate a risk for death. This is a new finding. The role of CD15s in infections is not very well known but increased numbers of CD15s positive neutrophils has been observed in neonatal sepsis. In vitro, incubation with IL-8 and f-MLP has been shown to cause a decrease in CD15 expression. Monocyte CD64 was highly upregulated in COVID-19 patients,
and this increase has also a predictive value for a poor outcome. This has not been reported before. The bearing of monocyte markers on mortality can be related to the ability of activated monocytes for cytokine production and regulating T-cells, as increased monocyte CD64 implies monocyte activation and cytokine production. On the other hand, the lack of relationship between neutrophil activation expressed as increase CD64 and mortality in our group was unexpected, as activation of neutrophils has been shown to predict critical illness and mortality in COVID-19. Neutrophil activation has also correlated with organ damage, and increased granulocytic CD64 has been shown to discriminate well between mild and severe forms of COVID-19.

Limitation of the study
Small number of patients and short time of observation are limiting factors of the study.

Conclusion
Neutrophils and monocytes are activated differently during severe COVID-19. Both have highly upregulated CD64. We propose that high neutrophil and monocyte CD64 can be used as a hallmark of severe COVID-19.

Adhesion molecules (CD11b, CD162, CD65 and CD15) are not upregulated on otherwise activated neutrophils, which can lead to relative impairment of tissue migration. Low adhesion profile of neutrophils suggests immune dysfunction. Monocytes maintained upregulation of some adhesion molecules (CD11b, CD162) suggesting the persistent increased ability to migrate into tissues, even during a severe stage of COVID-19. Future kinetic studies should examine whether neutrophil CD64 and CD11b expression, alone or in combination with other receptors, can be used as a predictive marker of prognosis in COVID-19.

Acknowledgements
The authors thank the study nurses, Elin Söderberg and Joanna Wessberg, and the biobank research assistants, Philip Karlsson and Erik Danielsson, for their expert help with compiling study data and organizing sample analysis. The authors thank laboratory technicians Lena Gröndahl, Annica Hult, Olga Golovko, and Eva Andersson for their skillful help in analyzing the samples.

Authors contributions
All authors contributed to the study conception and design. Material preparation and sample analyses were performed by Malgorzata Karawajczyk and Lena Douhan Håkansson. All authors participated in data analysis and interpretation. The first draft of the manuscript was written by Malgorzata Karawajczyk. All authors commented on previous versions of the manuscript, and all authors read and approved the final manuscript.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by the SciLifeLab/KAW national COVID-19 research program project grant to MH (KAW 2020.0182) and the Swedish Research Council to RF (2014-02569 and 2014-07606).

ORCID iD
Malgorzata Karawajczyk https://orcid.org/0000-0001-8192-0076

References
1. Liu J, Li H, Luo M, et al. Lymphopenia predicted illness severity and recovery in patients with COVID-19: a single-center, retrospective study. PLoS One 2020; 15: e0241659.
2. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020; 18: 206.
3. Mortaz E, Alipoor SD, Adcock IM, et al. Update on neutrophil function in severe inflammation. Front Immunol 2018; 9: 2171.
4. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. Epub ahead of print 1 June 2020. DOI: 10.1084/jem.20200652.
5. Bülow Anderberg S, Luther T, Berglund M, et al. Increased levels of plasma cytokines and
correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. *Cytokine* 2021; 138: 155389.

6. Vitte J, Diallo AB, Boumaza A, et al. A granulocytic signature identifies COVID-19 and its severity. *J Infect Dis* 2020; 222: 1985–1996.

7. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis* 2020; 71: 2459–2468.

8. Shallcross LJ and Davies DSC. Antibiotic overuse: a key driver of antimicrobial resistance. *Br J Gen Pract* 2014; 64: 604–605.

9. Cid J, Aguinaco R, Sánchez R, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis* 2019; 19: 56–66.

10. Vitte J, Diallo AB, Boumaza A, et al. A granulocytic signature identifies COVID-19 and its severity. *J Infect Dis* 2020; 222: 1985–1996.

11. Ioan-Facsinay A, de Kimpe SJ, Hellwig SMM, et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. *Immunity* 2002; 16: 391–402.

12. Borregaard N, Lollike K, Kjeldsen L, et al. Human neutrophil granules and secretory vesicles. *Eur J Haematol* 1993; 51: 187–198.

13. Cid J, Aguinaco R, Sánchez R, et al. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis. *J Infect* 2010; 60: 313–319.

14. Hashem HE, Abdel Halim RM, El Masry SA, et al. The utility of neutrophil CD64 and presepsin as diagnostic, prognostic, and monitoring biomarkers in neonatal sepsis. *Int J Microbiol* 2020; 2020: 8814982.

15. Lu L, Jin X and Zhang Q. CD35 and CD64 of neutrophils and monocytes in patients with influenza A, with and without complications. *Scand J Infect Dis* 2005; 37: 882–889.

16. Fjaertoft G, Pauksens K, Håkansson L, et al. Cell surface expression of FcgammaRII (CD64) on neutrophil and monocytes in patients with influenza A, with and without complications. *Scand J Infect Dis* 2005; 37: 882–889.

17. Jämsä J, Huotari V, Savolainen E-R, et al. Kinetics of leukocyte CD11b and CD64 expression in severe sepsis and non-infectious critical care patients. *Acta Anaesthesiol Scand* 2015; 59: 881–891.

18. Hu B-Q, Yang Y, Zhao C-J, et al. Accuracy of neutrophil CD64 expression in diagnosing infection in patients with autoimmune diseases: a meta-analysis. *Clin Rheumatol* 2019; 38: 1319–1328.

19. Muzlovic I, Ihan A and Stubljar D. CD64 index on neutrophils can diagnose sepsis and predict 30-day survival in subjects after ventilator-associated pneumonia. *J Infect Dev Ctries* 2016; 10: 260–268.

20. Jämsä J, Ala-Kokko T, Huotari V, et al. Neutrophil CD64, C-reactive protein, and procalcitonin in the identification of sepsis in the ICU - post-test probabilities. *J Crit Care* 2018; 43: 139–142.

21. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. *Cardiovasc Res* 2015; 107: 331–339.

22. Pauksens K, Fjaertoft G, Douhan-Håkansson L, et al. Neutrophil and monocyte receptor expression in uncomplicated and complicated influenza A infection with pneumonia. *Scand J Infect Dis* 2008; 40: 326–337.

23. Qiu X, Li J, Yang X, et al. Is neutrophil CD11b a special marker for the early diagnosis of sepsis in neonates? A systematic review and meta-analysis. *BMJ Open*. Epub ahead of print 1 May 2019. DOI: 10.1136/bmjopen-2018-025222.

24. Zhou H, Li Y, Gui H, et al. Antagonism of integrin CD11b affords protection against endotoxin shock and polymicrobial sepsis via attenuation of HMGB1 nucleocytoplasmic translocation and extracellular release. *J Immunol* 2018; 200: 1771–1780.

25. Zhang S, Song L, Wang Y, et al. Targeting CD162 protects against streptococcal M1 protein-evoked neutrophil recruitment and lung injury. *Am J Physiol Lung Cell Mol Physiol* 2013; 305: L756–L763.

26. Mallia P, Message SD, Contoli M, et al. Neutrophil adhesion molecules in experimental rhinovirus infection in COPD. *Respir Res* 2013; 14: 72.

27. Stålhammars ME, Sindelar R and Douhan Håkansson L. Neutrophil receptor response to bacterial N-formyl peptides is similar in term newborn infants and adults in contrast to IL-8. *Scand J Immunol* 2016; 84: 332–337.

28. Noguchi M, Sato N, Sugimori H, et al. A minor E-selectin ligand, CD65, is critical for
extravascular infiltration of acute myeloid leukemia cells. Leuk Res 2001; 25: 847–853.

29. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67–81.

30. Torsteinsdóttir I, Arvidson NG, Hällgren R, et al. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids. Scand J Immunol 1999; 50: 433–439.

31. Zhao L, Xu S, Fjaertoft G, et al. An enzyme-linked immunosorbent assay for human carcinoembryonic antigen-related cell adhesion molecule 8, a biological marker of granulocyte activities in vivo. J Immunol Methods 2004; 293: 207–214.

32. Hamblin A, Taylor M, Bernhagen J, et al. A method of preparing blood leucocytes for flow cytometry which prevents upregulation of leucocyte integrins. J Immunol Methods 1992; 146: 219–228.

33. Moreno RP, Metnitz PGH, Almeida E, et al. SAPS 3–from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005; 31: 1345–1355.

34. Simms H and D’Amico R. Regulation of polymorphonuclear neutrophil CD16 and CD11b/CD18 expression by matrix proteins during hypoxia is VLA-5, VLA-6 dependent. J Immunol Baltim Md 1950 1950; 150: 155: 4979–4990.

35. Leino L and Lilius EM. The up- and down-modulation of immunoglobulin G Fc receptors and complement receptors on activated human neutrophils depends on the nature of activator. J Leukoc Biol 1992; 51: 157–163.

36. Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med 2020; 26: 1701–1707.

37. Hashem HE, El Masry SA, Mokhtar AM, et al. Valuable role of neutrophil CD64 and highly sensitive CRP biomarkers for diagnostic, monitoring, and prognostic evaluations of sepsis patients in neonatal ICUs. BioMed Res Int 2020; 2020: 6214363.

38. Qin J-J, Cheng X, Zhou F, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension 2020; 76: 1104–1112.

39. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid-Based Med. Epub ahead of print 15 September 2020. DOI: 10.1136/bmjebm-2020-111536.

40. Krutmann J, Kirnbauer R, Köck A, et al. Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation. J Immunol Baltim Md 1950 1990; 145: 1337–1342.

41. Tanaka M, Krutzik SR, Sieling PA, et al. Activation of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses. J Immunol 2009; 183: 2349–2355.

42. Meizlish ML, Pine AB, Bishai JD, et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19. MedRxiv. Epub ahead of print 2 September 2020. DOI: 10.1101/2020.09.01.20183897.

43. Nicolai L, Leunig A, Brambs S, et al. Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. J Thromb Haemost. Epub ahead of print 20 November 2020. DOI: 10.1111/jth.15179.